Cohen Victor, Khuri Fadlo R
Sir Mortimer B. Davis-Jewish General Hospital, McGill University School of Medicine, Department of Oncology, Montreal, Quebec, Canada.
Curr Opin Pulm Med. 2004 Jul;10(4):279-83. doi: 10.1097/01.mcp.0000129754.97392.d5.
Lung cancer is one of the major causes of cancer-related deaths. Grim mortality figures argue powerfully for new approaches to control this disease. Chemoprevention is the use of specific natural or synthetic chemical agents to reverse, suppress, or prevent carcinogenic progression to invasive cancer. The current article focuses on the field of lung cancer chemoprevention and recent advances. Lung cancer biology and general principles of prevention strategies are also described.
Trials in lung cancer chemoprevention have so far produced either neutral or harmful primary end point results whether in the primary, secondary and tertiary settings. The data suggest that lung cancer was not prevented by beta-carotene, alpha-tocopherol, retinal, retinyl palmitate, N-acetylcysteine, or isotretinoin in smokers. The results from the recently completed Canadian study of anethole dithiolethione in smokers with bronchial dysplasia as well secondary analyses of the phase III trials involving selenium and data from the US Intergroup NCI-91-0001 supporting treatment with isotretinoin in never and former smokers are hopeful and may help define new avenues of chemopreventive treatment after scientists and clinicians analyze the information generated.
The concept of chemoprevention in lung cancer is still in its infancy but one day may have a significant impact on the incidence and mortality of this leading cancer threat. An improved understanding of carcinogenesis and cancer prevention mechanisms will no doubt aid in the design of future clinical trials and in the validation of candidate agents as well as the development of new targets. Planned or ongoing trials currently are targeting important molecular markers of lung carcinogenesis and progression including cyclooxygenase-2, the ras-signaling pathway through farnesyl transferase inhibitors and the tyrosine kinase/epidermal growth factor receptor pathway. Until such studies are completed however, no drug or drug combination should be used for lung cancer prevention outside of a clinical study.
肺癌是癌症相关死亡的主要原因之一。严峻的死亡率数据有力地表明需要采取新方法来控制这种疾病。化学预防是指使用特定的天然或合成化学制剂来逆转、抑制或预防致癌过程发展为浸润性癌症。本文重点关注肺癌化学预防领域及近期进展。还描述了肺癌生物学及预防策略的一般原则。
迄今为止,肺癌化学预防试验在一级、二级和三级预防环境中产生的主要终点结果要么是中性的,要么是有害的。数据表明,β-胡萝卜素、α-生育酚、视黄醛、棕榈酸视黄酯、N-乙酰半胱氨酸或异维甲酸并不能预防吸烟者患肺癌。最近完成的加拿大针对患有支气管发育异常的吸烟者进行的茴芹脑二硫醇硫酮研究结果,以及对涉及硒的III期试验的二次分析,还有美国肿瘤协作组NCI-91-0001研究中支持对从不吸烟和曾经吸烟的人使用异维甲酸治疗的数据,都给人带来希望,在科学家和临床医生分析所产生的信息后,可能有助于确定化学预防治疗的新途径。
肺癌化学预防的概念仍处于起步阶段,但有朝一日可能会对这一首要癌症威胁的发病率和死亡率产生重大影响。对致癌作用和癌症预防机制的更好理解无疑将有助于未来临床试验的设计、候选药物的验证以及新靶点的开发。目前正在进行或计划开展的试验针对的是肺癌发生和发展的重要分子标志物,包括环氧合酶-2、通过法尼基转移酶抑制剂作用的ras信号通路以及酪氨酸激酶/表皮生长因子受体通路。然而,在这些研究完成之前,除临床研究外,不应使用任何药物或药物组合来预防肺癌。